πŸ‡ΊπŸ‡Έ FDA
Patent

US 12213985

Oral cannabinoid formulations

granted A61KA61K31/05A61K31/658

Quick answer

US patent 12213985 (Oral cannabinoid formulations) held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/05, A61K31/658, A61K47/10, A61K47/14